In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step. An important point to note is that stocks can witness price or time correction. This column focuses on stagnating blue-chip stocks (time correction) that can awaken and surge higher.It’s not uncommon for investors to lose interest in stocks that have remained sideways for an extended period. That translates into undervaluation, and the stagnating ...

AstraZeneca (AZN) announced a definitive agreement to acquire Fusion Pharmaceuticals (FUSN) , which will add next-generation radioconjugates, a promising modality in cancer treatment, to its cancer pipeline.AstraZeneca has offered to acquire Fusion, a Canadian company, for a price of $21.00 per share in cash, which represents a premium of 97% to the latter’s closing price of $10.64 on Monday, Mar 18. In addition, AstraZeneca will be entitled to make a non-transferable contingent value (CV) payment of $3.00 ...

The latest trading session saw Astrazeneca (AZN) ending at $65.86, denoting a +0.02% adjustment from its last day's close. This change lagged the S&P 500's 0.57% gain on the day. Meanwhile, the Dow experienced a rise of 0.83%, and the technology-dominated Nasdaq saw an increase of 0.39%.Heading into today, shares of the pharmaceutical had gained 2.46% over the past month, outpacing the Medical sector's gain of 0.13% and lagging the S&P 500's gain of 2.97% in that time.The investment community will be paying ...

AstraZeneca (AZN) announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rival Boehringer Ingelheim earlier this month.This cap would apply to all of AstraZeneca’s inhaled respiratory products, which include Airsupra, Bevespi Aerosphere, Breztri Aerosphere and Symbicort.However, the company plans not to start this until June 2024. The British drugmaker is one of the biggest sellers of inhalers in the United State ...

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share. As part of the deal, AZN will gain access to the cancer specialist's most advanced program, FPI-2265, which focuses on prostate cancer. In response, Wedbush cut its rating to "neutral" from "outperform," while Jefferies downgraded the shares to "hold" from "buy," though both firms hiked their price-target hikes. No brokerage in ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs have emerged as a promising modality in cancer ...

AstraZeneca PLC (LSE:AZN) is acquiring clinical-stage oncology group Fusion Pharmaceuticals in a $2.4 billion (£1.9 billion) deal. The offer represents a massive 126% premium to Nasdaq-listed Fusion’s Monday closing price. AstraZeneca will pay $2 billion upfront at $21 per share followed by a contingent $3 per share “upon the achievement of a specified regulatory milestone”. Fusion “will complement AstraZeneca's leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most ...

MENLO PARK, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform. This assay has been validated for recurrence risk classification in newly diagnosed Stage I lung adenocarcinoma. GRAIL’s Methylation Platform enab ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease (COPD), including those who are uninsured and underinsured. Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ As ...